TOLVAT contains tolvaptan belongs to a group of medicines called vasopressin antagonists. This medicine is indicated in Autosomal dominant polycystic kidney disease” (ADPKD) and also clinically significant hypervolemic and euvolemic hyponatremia in adults with conditions such as heart failure, liver disease, and certain hormone imbalances. Vasopressin by reducing urine output causes fluid retention and prevent the loss of water from the body. Autosomal dominant polycystic kidney disease” (ADPKD) is a condition where fluid-filled cysts grow in the kidneys leading to increased pressure on the surrounding tissues that impairs the kidney function leading to kidney failure.
TOLVAT prevents the vasopressin having effect on the water retention. This reduces the amount of water in the body which slows the growth of kidney cysts in patients with ADPKD, reduces symptoms of the disease and increases urine production. It also increases the sodium and salt levels in your blood by removing extra water content in the body as urine in patients with heart failure, liver disease, and certain hormone imbalances.